Glutathione transferase in the urine: A marker for post-transplant tubular lesions  by Bäckman, Lars et al.
Kidney International, Vol. 33 (1988), PP. 571—577
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Glutathione transferase in the urine: A marker for post-transplant
tubular lesions. Basic glutathione transferase released from the proxi-
mal tubular epithelium in the kidney was monitored in the urine of 69
recipients of renal allografts. The enzyme was isolated from human
liver and the urinary analysis performed with radioimmunoassay.
Patients receiving cyclosporine A without toxicity or rejection did not
excrete this enzyme in their urine; whereas the urine of patients with
cyclosporine A-induced nephrotoxicity contained significant amounts
of the transferase (P < 0.001). Patients with allograft rejection also
showed increased urinary concentrations of the basic glutathione trans-
ferase, but had significantly lower values than patients with cyclospo-
rine induced nephrotoxicity (P < 0.001). During aminoglycoside and
co-trimoxazole treatment, the urinary concentration of this transferase
also increased. Patients with renal infarction showed a sudden increase
in urinary transferase to very high levels. The results indicate that
quantitative analysis of the basic glutathione transferase in urine is
useful for monitoring renal tubular lesions present in various complica-
tions following transplantation, such as cyclosporine and antibiotic
induced nephrotoxicity and renal infarction.
The release of cyctoplasmic enzymes as a result of an
increased permeability of the plasma membrane during various
pathological conditions is established in diagnosing many dis-
orders. Determination of a protein as such or of enzyme activity
in serum and plasma is used in diagnosing heart and liver
diseases [1, 2]. In case of the kidney this approach is less
developed. However, the idea of analyzing proteins in the urine
to diagnose renal diseases is not new [3]. Theoretically, an
increased permeability of renal epithelial cells may lead to
release of cytoplasmic proteins into the urine.
Glutathione transferases (GSH-transferases) play an impor-
tant role in conjugation reactions and are present at high levels
in the liver and kidney. Three major forms—basic, neutral and
acidic—have been identified and isolated from human tissues,
and it is probable that each major form consists of subgroups of
isoenzymes [4, 5].
The basic GSH-transferase (mol wt 51,000), formerly known
as ligandin, was reported to be localized in the proximal tubular
epithelium in the kidney [6]. Earlier investigations have de-
tected the enzyme in urine, which is normally free from
GSH-transferases, as a result of leakage from damaged tubular
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cells and not as a result of increased glomerular filtration of the
blood enzymes [7]. Zalneraitis, Arias and Cho observed GSH-
transferase in the perfusates from cadaveric kidneys collected
for transplantation showing acute tubular necrosis [8].
Cyclosporine A (CsA), known to be nephrotoxic, is reported
to affect the renal proximal tubular epithelium [9, 10], raising
the possibility that the appearance of basic GSH-transferase in
urine may be an indicator of CsA-induced nephrotoxicity.
We have developed a radioimmunoassay (RIA) using human
liver basic GSH-transferase as antigen, and utilized this proce-
dure to evaluate the usefulness of analyzing basic GSH-trans-
ferase levels in urine to diagnose tubular disorders as well as to
discriminate between CsA-induced nephrotoxicity and rejec-
tion in renal allograft recipients. The results indicate that this
approach will be useful foç monitoring renal tubular lesions
present in various complications following transplantation.
Methods
Sixty-nine recipients of renal allografts (28 females and 41
males) with a median age of 40 years (range 6 to 69) were
studied. These patients had received grafts from a total of 14
living and 55 cadaveric donors. Eight of the patients received
their second renal allograft and 16 underwent a combined
pancreatic and renal transplantation [11]. CsA and prednisolone
was used in 48 patients; azathioprine (AZA) and prednisolone
in 14 patients; and CsA, AZA and prednisolone were adminis-
tered together in 7 patients [12, 13]. Forty-two patients were
followed daily from transplantation until discharge from the
hospital, and twice weekly for a total of three months. The
patients were examined upon admittance to the hospital to
confirm the diagnoses of deterioriation in renal function. In
order to diagnose the different renal transplant deteriorations,
the practical approaches applied daily in clinical transplantation
were employed, such as morphological and radiological exam-
inations, clinical chemical parameters, and clinical response of
renal function to a given treatment.
Twenty-eight patients with stable renal function, referred to
as the stable group, were studied. They had serum creatinine
levels below 200 mol/liter and were free from rejection,
clinically significant CsA-induced nephrotoxicity, hypertension
and infection. This limit was used since CsA treated patients in
general have higher serum creatinine levels. In this group 23
patients received CsA, 2 patients AZA, and 3 received CsA,
AZA and prednisolone.
571
572 Backman et al: Glutathione transferase in the urine
Acute tubular necrosis, rejection, nephrotoxicity and renal
infarction
Acute tubular necrosis (ATN) was presumed to be present in
patients requiring dialysis due to uremia after the renal trans-
plantation (N = 9), if no other reason for the impairment could
be established. In 33 patients improvement in renal function
was immediate. Samples from the first post-operative day were
used for comparisons. Theoretically, it is possible that patients
with a mild form of ATN not requiring dialysis were placed in
the group with an immediate onset in renal function here. An
absolute diagnosis of ATN in the post-transplant period would
require a biopsy, which was, however, not possible.
A biopsy from the graft was taken in 32 of the patients with
increased serum creatinine. In those cases where the morpho-
logical changes were compatible with rejection (N = 21) or if
there was strong clinical suspicion, anti-rejection therapy was
given (N = 38). If the morphological examination revealed no
signs of acute rejection in patients treated with CsA (N = 11),
nephrotoxicity was assumed and the dosage of CsA reduced. In
cases where no biopsy was taken, the diagnosis of CsA neph-
rotoxicity was made if the graft function improved after reduc-
tion of the CsA dose (N = 16). Anti-rejection treatment
consisted of 0.5 g methylprednisolone intravenously (i.v.) for
one day, followed by 0.25 g for at least three additional days
(range 3 t 8 days). Eighteen patients treated with CsA, 14
treated with AZA and 6 patients treated with both CsA and
AZA suffered rejection episodes. Renal allograft infarction (N
= 3) was diagnosed by renal angiogram. The infarctions were
total in two cases and partial in one. One patient developed a
venous thrombosis in the allograft, diagnosed by renal angi-
ogram. One patient suffered from hydronephrosis due to al-
lograft uretary stenosis diagnosed by ultrasound examination.
In cases of rejection, CsA nephrotoxicity, infarction and hydro-
nephrosis, the values on the day of diagnosis were used for
comparison.
Antibiotic treatment
Six patients with infections were treated with netilmicin (2
mg/kg body wt/dose) in combination with co-trirnoxazole. The
dose interval was based on renal function and on serum levels
of netilmicin. Co-trimoxazole was given either orally or intra-
venously at a dose of 640 mg trimetoprim and 3400 mg sulpham-
etoxazole per day with precaution to the renal function Two
patients were treated with netilmicin or co-trimoxazole alone.
The maximal concentration of OSH-transferase during the
treatment, together with the concomitant serum creatinine
level, were compared with the values obtained immediately
before treatment.
Protein purjfication and iodination
Basic GSH-transferase from a human liver was purified
according to Warholm et al [5] with certain modifications. The
105,000 g supernatant fraction was filtered through a Sephadex
0-25 column (Pharmacia, Uppsala, Sweden) equilibrated with
100 mti Tris-HC1 buffer, pH 7.8, containing 1 mM EDTA. The
fractions containing GSH-transferase activity were applied to a
DEAE-cellulose column. The protein was further purified by
affinity chromatography on S-hexylglutathione coupled to ep-
oxy-activated Sepharose 6B. The active fractions were desalted
on a Sephadex 0-25 column and concentrated in an Amincon
ultrafiltration cell. GSH-transferase activity was measured spec-
trophotometrically at 340 nm with l-chloro 2,4-dinitrobenzene
as substrate. The purified enzyme was labeled with 1 mCi 1251
(Amersham International, Arlington Heights, Illinois, USA)
[14], followed by removal of unbound 1251 on a Sephadex 0-25
column. The labeled protein was purified on a affinity column
before being used as tracer in the assay.
Antibody production
Rabbits were injected in the foot pads with 0.3 ml Freunds
complete adjuvant (FCA; Gibco, London, UK), enlarging the
lymph nodes in the knee joints. The purified protein (50 to 70
jig) in FCA was then injected into these lymph nodes. This
procedure was repeated several times. Blood was tapped and
antiserum prepared. The specificity of the antiserum was con-
firmed using the 105,000 g supernatant fraction and human
neutral and acidic GSH-transferases as antigens for Ouch-
terlony gel diffusion [15].
Radioimmunoassay
Mter titration, the antiserum was used at a dilution of
1:175,000. The standard curve, constructed according to the
Spline function [16], consisted of 12 duplicate samples of the
purified protein in 0.05 M potassium phosphate buffer, pH 7.4,
containing 0.15 M sodium chloride, 10 mtc EDTA, 1.0% bovine
serum albumin and 0.1% sodium azide. The concentrations
ranged from 1.0 to 1,000 ng/ml. Urine was collected and stored
at room temperature without addition of protease inhibitors.
This storage did not influence the enzyme levels measured with
RIA. Samples were centrifuged and frozen at —20°C. Duplicate
samples consisting of 100 /4 urine were mixed with 100 /4
(20,000 dpm) tracer and 100 .d diluted antiserum. The mixture
was shaken at room temperature for 20 hours. Two hundred
fifty microliters (1 mg) of goat-antirabbit secondary antibody
(Immunobead reagent, Bio-Rad Laboratories, Richmond, Cal-
ifornia, USA) was then added and incubated for two hours at
37°C. Each sample was washed with 2 ml of the MA buffer. The
samples were centrifuged at 1500 g for 10 minutes and decanted.
The radioactivity in the pellet was counted and the enzyme
amount calculated from the standard curve.
Analysis of creatinine
Serum creatinine (Scr), normal value <115 jimollliter, was
analyzed using the kinetic Jaffe method. The accuracy of this
method has been evaluated using isotope dilution mass spec-
trometry [17].
Statistics
For comparisons between the different groups the Mann-
Whitney U-test was used. Students t-test, chi-square analysis
and Fishers exact test were also used when appropriate. The
linear correlation coefficient was calculated. OSH-transferase
concentratiOns of less than 1 ng/ml were arbitrarily assigned the
value 0.5 ng/ml for the statistical analyses.
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Table 1. Purification of bas ic glutathione transferase from human liver
Protein Specific activity Yield of
Volume concentration Total activity smol/min/mg Purification activity
Step ml mg/mi j.imol/min protein factor %
Cytosolic fraction 100 13.9 5400 3.9 1 100
SephadexG-25 140 9.2 5230 4.1 1.1 96.9
DEAE-cellulose 175 1.5 4060 15.5 4.0 75.2
Affinity chromatography + sephadex
G-25 concentration 86 0,11 2511 265.4 68.1 46.5
Amincon cell 10 0.91 2340 257.1 65.9 43.3
Results
Protein purification
This study required the isolation of a highly purified human
basic GSH-transferase to be used as antigen for the antibody
production and as tracer and standards in the RIA. The gel
filtration and ion exchange chromatography resulted in a limited
purification. Successful isolation required the use of affinity
chromatography. The purification factor with this step included
was about 70 (Table 1) and the yield was 40 to 50% of the
cytosolic activity. The purity of the isolated enzyme was
investigated by sodium dodecylsulphate (SDS)-gel electropho-
resis (Fig. 1). Coomassie Blue staining showed a single and
well-defined band with an apparent molecular weight of 26,000
for the two subunits. No contaminating bands were visible.
Antiserum and tissue localization
The anti-serum had a titer of 1:175,000. Single precipitations
were obtained upon immunodiffusion with the 105,000 g super-
natant fraction or the purified GSH-transferase. No precipita-
tions were obtained when human neutral or acidic transferases
were tested.
Immunohistochemical staining of formalin fixed non-patho-
logical renal biopsies with use of the antiserum, and the
horseradish peroxidase reaction showed an intense positive
reaction in the proximal tubular epithelium (Fig. 2). Staining of
biopsies from patients with CsA nephrotoxicity did not reveal
any alteration in the distribution of the transferase.
Stable renalfunction and ATN
Patients who belonged to the stable group had a 5Cr level of
133 8 tmol/liter (mean SEM; Fig. 3). They demonstrated a
somewhat impaired renal function in comparison to a healthy
population (Sc. <115 mol/liter). The level of basic GSH-
transferase was 0.7 0.4 ng/ml (mean sEM) in the patients
with stable renal function. About 80% (22 of 28) had a level less
than 1.0 ng/ml. Of all measurements on patients with stable
renal function (N = 298) 12% showed values greater than 1.0
nglml.
During ATN the 5Cr level was higher (P < 0.001) than in
patients with an immediate onset of renal function, the mean
values being 1041 71 and 461 40 prnol/liter (±sEM),
respectively. The urinary GSH-transferase concentration was
also significantly higher in the ATN group (p < 0.05) in
comparison with patients demonstrating an immediate onset in
renal function (19.8 8.1 and 7.1 2.0 ng/ml, mean SEM,
respectively).
92.5k
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Fig. 1. Appearance of purfled glutathione transferase on a polyacryl-
amide gel. SDS-PAGE was performed in a 1.5 mm thick 10% polyacryl-
amide gel. Twenty sg of the purified protein and the standards were
electrophoresed at 30 mA in 0.05 M Tris-HC1, 0.38 M glycine, 0.1%
SDS, pH 8.3, in a vertical slab gel unit and stained with Coomassie
Blue. On the left side are the references used: lysozyme (mol wt 14,400),
soybean trypsin inhibitor (21,500), carbonic anhydrase (31,000), oval-
bumin (45,000), bovine serum albumin (66,200) and phosphorylase B
(92,500). On the right side are the subunits of the purified human liver
basic GSH-transferase, overlapping each other with a molecular weight
of approximatively 26,000.
Renal infarction and hydronephrosis
In the three cases of renal infarction the urinary GSH-
transferase concentration was 134 90 nglml (mean SEM) and
the mean Sr level was 420 142 jmolIliter (± SEM). The
patient with a venous thrombosis in the renal allograft had a
aS
S
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Fig. 2. Immunohistochemical staining of a human kidney biopsy with rabbit anti-human basic glutathione transferase serum. The formalin-fixed
slices were incubated with the antiserum in a dilution of 1:200. The antigen-antibody complex was visualized by the horseradish peroxidase
technique. Positive reaction was only visible in the proximal tubular epithelium. Staining after incubation with antigen absorbed or nonimmune
serum was negative. Magnification x400.
XH-+ 1-
n28 n=38 n=27
Stable Rejection GSA- Stable Rejection GSA-
tox. tox
Fig. 3. Serum creatinine and urinary GSH-transferase concentrations
in renal transplant recipients. The criteria for stable, rejection and
cyclosporine induced nephrotoxicity are given in Methods, N = number
of patients. The horizontal line is the mean value, while the vertical bar
indicates 5EM.
transferase concentration of greater than 1,000 nglml. In these
&atients the increased urinary concentration was observed on
the same day as the increased Scr. In the case of hydronephro-
sis there was no detectable GSH-transferase in the urine.
Rejection and CM -induced nephrotoxicity
Patients with acute rejection had a Scr of 283 21 tmoI/liter
(mean 5EM; Fig. 3), significantly higher than for patients with
stable renal function (P <0.001). The urinary USH-transferase
concentration for the rejection group was 1.7 0.3 nglml (mean
saM), also differing from the stable group (P < 0.001). In
comparison with the ATN and "immediate onset" groups,
those with rejection had significantly lower GSH-transferase
concentrations in their urine (P C 0.001 and P C 0.01, respec-
tively).
In patients with CsA-induced nephrotoxicity the Scr (235
20 jzmol/liter, mean SEM) was increased in comparison to the
stable group (P C 0.001). However, patients with acute rejec-
tion had a higher Ser level than those with acute CsA nephro-
toxicity (P C 0.05). The concentration of basic GSH-transferase
in the urine in case of toxicity was 4.1 0.6 ng/ml, (mean
SEM), exceeding the values for the stable (P C 0.001) and
rejection groups (P C 0.001). A urinary OSH-transferase value
greater than 2 nglml was seen in 21 of 27 (78%) of the patients
diagnosed to have CsA nephrotoxicity, and only in 8 of 38(21%)
of the patients with rejection (P C 0.001, chi-square analysis).
To determine whether CsA-induced nephrotoxicity was also
present in the eight patients with high urinary GSH-transferase
levels and rejection, those treated with AZA, or experiencing
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re-rejection episodes or irreversible rejections were excluded.
The three remaining patients with the highest GSH-transferase
levels all developed nephrotoxicity within six months, while
only two of the corresponding 12 patients in the group with
urinary concentrations less than 2 ng/ml suffered a CsA neph-
rotoxic episode within six months (P < 0.05, Fishers' exact
test).
During CsA-induced nephrotoxicity there was no linear cor-
relation (r = 0.16, NS) between Scr and the GSH-transferase
concentration in the urine. The correlation between urinary
GSH-transferase concentration and the amount excreted per
minute was linear in the patients with CsA nephrotoxicity (r
0.95, P < 0.001; Fig. 4).
Of the patients with CsA nephrotoxicity 13 underwent daily
monitoring of GSH-transferase. In nine (69%) of these patients
the GSH-transferase concentration increased at the same day as
did the SCr. In two patients the increase occurred one day
before and in two patients two days before the increase in Sr.
During episodes of nephrotoxicity 77% of the GSH-transferase
values were increased during the five day period after the
diagnosis was made. Of the 25 patients with acute rejection and
urinary GSH-transferase concentrations greater than 1 ng/ml,
16 underwent daily monitoring and 81% of these demonstrated
elevated levels within five days after diagnosis.
Antibiotic treatment
In 10 patients treated with netilmicin alone and/or co-trimoxa-
zole, the GSH-transferase level in the urine increased from 0.7
0.1 ng/ml (±sEM) before treatment to a maximum of 3.1 0.8
ng/ml (mean SEM, P < 0.001; Table 2). The mean SCr level
increased from 203 42 to 279 56 mol/liter (± SEM, P <
0.01) on the day when the maximal GSH-transferase was
attained.
The values for a 26-year-old male pancreatic and renal graft
recipient who underwent netilmicin treatment due to septicemia
are shown in Figure 5. The SCr level was only slightly elevated,
while the GSH-transferase level in the urine increased contin-
uously and considerably during the period.
Discussion
GSH-transferases are present in many different tissues and
play a central role in the biotransformation of drugs and toxic
chemicals. Their catalytic action produces glutathione conju-
gates, which are either excreted or hydrolyzed to cysteine
derivates, and subsequently N-acetylated to yield mercapturic
acids [18]. The basic form has been identified in the liver,
kidney, adrenal gland, duodenum and gonads [19, 201. The
enzyme is present in high concentrations constituting 5% and
2% of the cytoplasmic protein content in the liver and proximal
tubules of the kidney, respectively.
The basic isolated GSH-transferase demonstrated a high
2 specific activity and was found to be pure; the antisera did notcross-react with the neutral or acidic forms of the enzyme.
There are two explanations for the appearance of GSH-
transferase in urine: excretion from plasma by glomerular
filtration or release from damaged cells in the proximal tubular
epithelium. It has been reported that glomerular disorders do
not increase the urinary excretion of GSH-transferase, making
the first explanation unlikely [7].
In patients with ATN the urinary GSH-transferase concen-
tration was higher than in patients with immediate onset in renal
function after transplantation, which may be useful in differen-
tial diagnosis for example, low GSH-transferase concentrations
in spite of high SCr values may indicate the absence of ATN or
CsA nephrotoxicity. Urinary GSH-transferase excretion was
massive during allograft infarction. This finding is useful for an
early diagnosis of allograft infarction, since potentially-danger-
ous immunosuppressive treatment can then be stopped.
Two major complications often occur after renal transplanta-
tion in patients receiving CsA: acute rejection and CsA-induced
nephrotoxicity. Monitoring of blood and plasma levels of CsA is
of limited value in detecting toxicity, since there seems to be
only a small difference between the therapeutic and toxic levels
of CsA, and which sometimes appear to overlap [21]. Methods
for distinguishing between these conditions are limited. The
most effective are needle biopsy and fine needle aspiration
biopsy [22—25].
CsA-induced nephrotoxicity in human renal transplant recip-
ients was accompanied by a release of basic GSH-transferase in
the urine, indicating a toxic effect of the drug on the proximal
tubular system. CsA has several well-defined effects on peroxi-
somes and microsomes [261. Experimental and clinical studies
of CsA-induced toxicity have revealed histological changes in
the proximal tubules [9, 10, 27]. However, we cannot exclude
the possibility that CsA also affects other parts of the kidney.
The patients suffering acute rejection usually had a moder-
ately elevated level of basic GSH-transferase in their urine, but
the level was significantly below the level obtained during CsA
nephrotoxicity. However, Se,. levels were higher in patients
with rejections than in those with CsA-induced nephrotoxicity.
In some cases of rejection elevated urinary levels of transferase
0.95, P<0.001
N= 27
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Fig. 4. Correlation between urinary GSH-transferase concentration
and the amount of enzyme excreted per minute in the urine during
cyclosporine induced nephrotoxicity.
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Table 2. Effect of antibiotic treatment on glutathione transferase concentration in urine and serum cre atinine level
Serum creatinine concentration
Urinary GSH-transferase
concentration ng/ml
tmo1/liter
When GSH-Maximal
Patient Before value during Before transferase
no. Antibiotic treatment treatment treatment treatment was maximal
1 Co-trimoxaxole, p.o. 0.5 1.6 202 269
2 Co-trimoxazole, p.o. 0.5 1.3 69 85
3 Netilmicin 0.5 7.8 246 255
4 Netilmicin 1.1 1.6 196 279
5 Co-trimoxazole, i.v. + netilmicin 0.5 0.5 62 85
6 Co-trimoxazole, i.v. + netilmicin 0.5 2.1 185 325
7 Co-trimoxazole, i.v. + netilmicin 0.5 1.0 524 679
8 Co-trimoxazole, i.v. + netilmicin 0.5 5.1 273 285
9 Co-trimoxazole, i.v. + netilmicin 0.5 6.0 167 413
10 Co-trimoxazole, i.v. + netilmicin 1.4 3.6 105 113
Mean±sEM 0.7±0.1 3.1±0.8 203±42 279±56
Significancea P < 0.01 P C 0.01
The maximal urinary GSH-transferase concentrations attained during the antibiotic treatment and serum creatinine values measured on the same
day were used.
a Levels of significance were determined by the Mann-Whitney U-test.
1000
500
0
Fig. S. Effect of aminoglycoside treatment on urinary glutathione
transferase concentration. The values are for a 26-year-old male
recipient of a pancreatic and renal allograft suffering from a Klebsiella
enterobacterium septicemia diagnosed with a positive blood culture on
day 75 after transplantation. Netilmicin was given intravenously at a
dose of 100 mg124 hour (2 mglkg body wt). The serum concentration of
netilmicin was 1.9 pg/ml immediately before administration on day 77
and 7.6 tg/ml 1 hour after administration. The patient was treated with
azathioprine (AZA) and prednisolone, but the AZA treatment was
discontinued due to the severe infection. (—) Urinary glutathione
transferase concentration; (---) serum creatinine level.
were obtained, which is not surprising, since some degree of
toxicity induced by CsA or other factors may also be present. In
some case of nephrotoxicity the level of transferase in urine was
not elevated, while in some cases of rejection it was elevated to
the same level as in the toxicity group. We have no immediate
explanation for these findings. Future studies regarding sub-
groups (that is, released isoenzymes not detected by our
antibodies), other associated pathological conditions and the
influence of other drugs, may provide some answers. It is
possible that a severe rejection episode might give rise to
tubular damage, followed by a pronounced excretion of basic
GSH-transferase. On the other hand, in our material not even
the patients with the most severe and irreversible rejections
displayed such increased excretion. In most cases then, obvi-
ously, rejection episodes were not accompanied by any marked
effects on the tubular cells containing the basic OSH-trans-
ferase.
The antibiotics co-trimoxazole and aminoglycosides are known
to be nephrotoxic [28] and have been reported to potentiate
CsA-induced nephrotoxicity [29, 30]. During netilmicin treat-
ment no patient had extreme levels of the drug in his serum. The
increase in GSH-transferase suggests that this enzyme is a more
sensitive indicator of tubular damage than serum creatinine
levels.
The results demonstrate that quantitation of basic GSH-
transferase in urine is a useful method in detecting and moni-
toring disturbances of tubular function. The test developed was,
in fact, specific for the detection of tubular damage and,
therefore, useful for detecting different pathological conditions
giving rise to tubular epithelial damage. This enzyme excretion
was increased during several conditions, but the degree of
excretion, its time course and the clinical circumstances may be
of help in differentiating between various disturbances of the
tubular system.
Epithelial cells in the nephron differ both in chemical and
enzymatic composition [31, 32]. In the future isolation of
proteins present at high concentrations in specific tubular cells
and their use for quantitation in urine may therefore be of
importance. There are good reasons to believe that establish-
ment of a few assays for specific proteins in urine wifi provide
improved tools for diagnosis of renal impairments, such as
F— Netilmicin treatment
75 80
Time, days post-transplant
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those available for analysis of disturbances in liver and heart
function.
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